Shares of Menlo Therapeutics Inc (NASDAQ:MNLO) have received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price target of $45.67 for the company, according to Zacks. Zacks has also assigned Menlo Therapeutics an industry rank of 182 out of 265 based on the ratings given to related companies.
Several equities analysts have issued reports on the stock. Jefferies Group assumed coverage on shares of Menlo Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $41.00 price objective for the company. Piper Jaffray Companies assumed coverage on shares of Menlo Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $48.00 price objective for the company. JMP Securities assumed coverage on shares of Menlo Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $44.00 price objective for the company. Finally, Guggenheim assumed coverage on shares of Menlo Therapeutics in a research note on Monday. They issued a “buy” rating and a $52.00 price objective for the company.
In related news, major shareholder Vivo Capital Surplus Fund Viii acquired 294,118 shares of the firm’s stock in a transaction on Thursday, January 25th. The stock was bought at an average price of $17.00 per share, for a total transaction of $5,000,006.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Menlo Therapeutics (NASDAQ MNLO) opened at $33.96 on Wednesday. Menlo Therapeutics has a 12 month low of $20.50 and a 12 month high of $39.86.
TRADEMARK VIOLATION WARNING: This report was originally reported by Stock Observer and is owned by of Stock Observer. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thestockobserver.com/2018/02/21/zacks-menlo-therapeutics-inc-mnlo-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
About Menlo Therapeutics
Menlo Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The Company offers VPD-737 (serlopitant), a potent oral NK1 receptor antagonist for the treatment of severe, chronic pruritus associated with or without a diagnosed disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Menlo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Menlo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.